CarePal Money, India's first integrated healthcare lending marketplace and subsidiary of CarePal Group, has achieved an annualised disbursement run rate of ₹150 crore, representing a 50% increase from the ₹100 crore achieved just months ago. According to reports from The Hindu BusinessLine, this growth underscores the accelerating demand for structured healthcare financing in the Indian market.
The platform enables patients to finance treatments through no-cost and low-cost EMI loans, covering minor procedures to high-value cases exceeding ₹25 lakh for cancer care and organ transplants. As reported by The Hindu BusinessLine, for hospitals, this translates into improved elective treatment conversions, faster discharges and significantly fewer cases of patients leaving mid-treatment due to financial constraints. CarePal also offers a reimbursement financing service that allows hospitals to extend short-term loans to patients whose insurance provider is not empanelled with the hospital.
According to the company data reported by The Hindu BusinessLine, Medical Management leads the disease mix at 33% of loans disbursed over the past 2.5 years, followed by Cardiology at 15% and Neurology at 14%, collectively representing over 60% of all disbursements. High-value specialties such as oncology, nephrology, pulmonology, and liver surgery continue to constitute a growing share of the portfolio.
Piyush Jain, Co-Founder & CEO, CarePal Group, stated that reaching ₹150 crore in annualised disbursements is a strong validation of the model that works for patients, hospitals and lenders alike. As reported by The Hindu BusinessLine, with over 40% of healthcare costs still paid out-of-pocket in India, the company remains committed to scaling to over ₹2,000 crore annual disbursements in the next five years. Sahil Lakshmanan, CEO, CarePal Money, emphasized that the company's zero interest model removes one of the biggest cost barriers for patients.
